The short version of immune modulation fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-15 and is reviewed periodically as new material appears.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈3,108 Da | Synthetic 28-residue peptide |
| Amino acid count | 28 | N-terminal serine carries an acetyl group |
| Appearance | White to off-white powder | Lyophilized solid |
| Water solubility | Freely soluble | Dissolves in aqueous buffer |
| Common synonyms | Thymalfasin; Tα1 | Thymalfasin is the international nonproprietary name |
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
Its main geographical units are: the Coastal Plain along the Gulf of Guinea, the Ashanti uplands in the centre, the Volta Basin in the east, which is dominated by Lake Volta, and the Northern Plains stretching to Burkina Faso. The highest point is Mount Afadja (885 m) in the Akwapim-Togo Range. The northernmost settlement in Ghana is Pulmakong near the Burkina Faso border, while the southernmost point is Cape Three Points.
Chapter 1: Multi-Species Waves and Practical Applications Chapter 2: Spatial Pattern Formation with Reaction Diffusion Systems Chapter 3: Animal Coat Patterns and Other Practical Applications of Reaction Diffusion Mechanisms Chapter 4: Pattern Formation on Growing Domains: Alligators and Snakes Chapter 5: Bacterial Patterns and Chemotaxis Chapter 6: Mechanical Theory for Generating Pattern and Form in Development Chapter 7: Evolution, Morphogenetic Laws, Developmental Constraints and Teratologies Chapter 8: A Mechanical Theory of Vascular Network Formation Chapter 9: Epidermal Wound Healing Chapter 10: Dermal Wound Healing Chapter 11: Growth and Control of Brain Tumours Chapter 12: Neural Models of Pattern Formation Chapter 13: Geographic Spread and Control of Epidemics Chapter 14: Wolf Territoriality, Wolf-Deer Interaction and Survival
Most important of all, the Butantan Institute became a fertile school for breeding a new generation of Brazilian biochemists, physiologists and pathologists, such as José Moura Gonçalves, Carlos Ribeiro Diniz, Gastão Rosenfeld, Wilson Teixeira Beraldo and Maurício Rocha e Silva, who went on to found a growing number of schools, departments and research laboratories in São Paulo, Rio de Janeiro and Minas Gerais, giving a great impetus to the development of medical and biological research and teaching in Brazil in the second half of the 20th century.
==== Medieval photography ==== The art historian Nicholas Allen has proposed that the image on the shroud could have been formed as early as the 13th century using techniques described in the 1011 Book of Optics. However, according to Mike Ware, a chemist and expert on the history of photography, Allen's proposal "encounters serious obstacles with regard to the technical history of the lens. Such claimants tend to draw upon the wisdom of hindsight to project a distorted historical perspective, wherein their cases rest upon a particular concatenation of procedures which is exceedingly improbable; and their 'proofs' amount only to demonstrating (none too faithfully) that it was not totally impossible." Among other difficulties, Allen's hypothesized process would have required that the subject (a corpse) be exposed in the sunlight for months.
Sources: en.wikipedia.org
==== General ==== Lower Saxony has clear regional divisions that manifest themselves geographically, as well as historically and culturally. In the regions that used to be independent, especially the heartlands of the former states of Brunswick, Hanover, Oldenburg and Schaumburg-Lippe, a marked local regional awareness exists. By contrast, the areas surrounding the Hanseatic cities of Bremen and Hamburg are much more oriented towards those centres.
The creation of URLs that will not change with time is the fundamental method of preventing link rot. Preventive planning has been championed by Tim Berners-Lee and other web pioneers. Berners-Lee recommended designing URIs to avoid details likely to change, such as authorship, subject matter, file extension, software mechanism, or access status. Strategies pertaining to the authorship of links include:
=== Circadian rhythm === There is evidence to suggest that adropin levels exhibit a circadian rhythm, meaning they follow a natural 24-hour cycle. Circadian rhythms play a vital role in regulating various physiological processes, including sleep-wake cycles, hormone secretion, and metabolism.
is/are adjudged an insolvent; or engage(s) during their term of office in any paid employment outside the duties of their office; or is/are, in the opinion of the president, unfit to continue in office because of infirmity of mind or body. The chairman or any other member cannot hold an office of profit or otherwise they shall be deemed to be guilty of misbehavior. The Union Public Service Commission shall be consulted on all matters relating to:
== Synthesis == It can be synthesized from catechol first by conversion to methylenedioxybenzene, which is brominated and coupled with allyl bromide. Safrole is a versatile precursor to many compounds. Examples are N-acylarylhydrazones and isosters, aryl-sulfonamide derivatives, acidic sulfonylhydrazone derivatives, benzothiazine derivatives and many more.
Sources: en.wikipedia.org
PA 6/66: [NH−(CH2)6−NH−CO−(CH2)4−CO]n−[NH−(CH2)5−CO]m made from caprolactam, hexamethylenediamine and adipic acid; PA 66/610: [NH−(CH2)6−NH−CO−(CH2)4−CO]n−[NH−(CH2)6−NH−CO−(CH2)8−CO]m made from hexamethylenediamine, adipic acid and sebacic acid. The term polyphthalamide (abbreviated to PPA) is used when 60% or more moles of the carboxylic acid portion of the repeating unit in the polymer chain is composed of a combination of terephthalic acid (TPA) and isophthalic acid (IPA).
=== Temporal low-voltage irregular delta wave === Temporal low-voltage irregular delta wave activity has been commonly detected in patients with ischemic brain diseases, particularly in association with small ischemic lesions and is seen to be indicative of early-stage cerebrovascular damage.
An epitope, () also known as antigenic determinant, is the part of an antigen that is recognized by the immune system, specifically by antibodies, B cells, or T cells. The part of an antibody that binds to the epitope is called a paratope. Although epitopes are usually non-self proteins, sequences derived from the host that can be recognized (as in the case of autoimmune diseases) are also epitopes. The epitopes of protein antigens are divided into two categories, conformational epitopes and linear epitopes, based on their structure and interaction with the paratope. Conformational and linear epitopes interact with the paratope based on the 3-D conformation adopted by the epitope, which is determined by the surface features of the involved epitope residues and the shape or tertiary structure of other segments of the antigen. A conformational epitope is formed by the 3-D conformation adopted by the interaction of discontiguous amino acid residues. In contrast, a linear epitope is formed by the 3-D conformation adopted by the interaction of contiguous amino acid residues. A linear epitope is not determined solely by the primary structure of the involved amino acids. Residues that flank such amino acid residues, as well as more distant amino acid residues of the antigen affect the ability of the primary structure residues to adopt the epitope's 3-D conformation. 90% of epitopes are conformational.
=== SELDI-TOF-MS === Samples spotted on a SELDI surface are typically analyzed using time-of-flight mass spectrometry. An irradiating laser ionizes peptides from crystals of the sample/matrix mixture. The matrix absorbs the energy of the laser pulse, preventing destruction of the molecule, and transfers charge to the sample molecules, forming ions. The ions are then briefly accelerated through an electric potential and travel down a field-free flight tube where they are separated by their velocity differences. The mass-to-charge ratio of each ion can be determined from the length of the tube, the kinetic energy given to ions by the electric field, and the velocity of the ions in the tube. The velocity of the ions is inversely proportional to the square root of the mass-to-charge ratio of the ion; ions with low mass-to-charge ratios are detected earlier than ions with high mass-to-charge ratios.
Sources: en.wikipedia.org
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.
It is usually described as an immunomodulatory peptide rather than a classic hormone. It acts on immune cells through receptor pathways. No single endocrine organ target defines its function.
Several countries, including Italy and China, allow it for specific indications. The FDA has not approved it as a drug in the United States. Availability depends on local regulation.
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.